Shire PLC (LON:SHP)‘s stock had its “buy” rating reiterated by stock analysts at Shore Capital in a research note issued to investors on Monday.
Other equities analysts have also issued reports about the stock. Liberum Capital reissued a “hold” rating and set a GBX 4,900 ($64.45) price objective on shares of Shire PLC in a report on Thursday, August 3rd. J P Morgan Chase & Co reissued an “overweight” rating on shares of Shire PLC in a report on Thursday, July 20th. Credit Suisse Group reissued an “outperform” rating and set a GBX 5,350 ($70.37) price objective on shares of Shire PLC in a report on Friday, August 4th. Beaufort Securities reissued a “long term buy” rating and set a GBX 4,900 ($64.45) price objective (down from GBX 6,200 ($81.55)) on shares of Shire PLC in a report on Friday, August 4th. Finally, Deutsche Bank AG reissued a “buy” rating and set a GBX 6,000 ($78.92) price objective on shares of Shire PLC in a report on Friday, August 4th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of GBX 5,358.82 ($70.48).
Shares of Shire PLC (SHP) opened at GBX 3,505 ($46.10) on Monday. Shire PLC has a 12 month low of GBX 3,435.50 ($45.19) and a 12 month high of GBX 5,107 ($67.17).
In related news, insider Flemming Ornskov acquired 8,400 shares of the stock in a transaction dated Tuesday, August 22nd. The stock was acquired at an average cost of GBX 3,665 ($48.20) per share, for a total transaction of £307,860 ($404,919.11). Also, insider Anne Minto acquired 190 shares of the stock in a transaction dated Friday, September 29th. The shares were bought at an average price of GBX 3,785 ($49.78) per share, with a total value of £7,191.50 ($9,458.77).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.